In summary, these data demonstrate that TGF-β signaling plays an important role in microenvironment-mediated chemoresistance in AML, and that TGF-β blockade in conditions of interacting hypoxia and BM stromal cells may be an effective new tool in the therapy of genetically diverse AML subsets. The gene discussed is TGFB1; the disease is acute myeloid leukemia.